Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Does earlier HIV RNA suppression provide long-term benefits?

Moyle G, Demasi R, Hill A.

AIDS. 2010 Jun 19;24(10):1591-3. doi: 10.1097/QAD.0b013e32833ad933.

PMID:
20479634
2.

Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.

Ananworanich J, Siangphoe U, Hill A, Cardiello P, Apateerapong W, Hirschel B, Mahanontharit A, Ubolyam S, Cooper D, Phanuphak P, Ruxrungtham K.

J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):523-9.

PMID:
16044002
3.

Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.

Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M, Phillips A, Staszewski S.

Antivir Ther. 2008;13(7):927-36.

PMID:
19043927
4.
5.

Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.

Pariente N, Pernas M, de la Rosa R, Gómez-Mariano G, Fernández G, Rubio A, López M, Benito JM, López-Galíndez C, Leal M, Domingo E, Martinez MA, Mas A.

J Med Virol. 2004 Jul;73(3):350-61.

PMID:
15170628
7.

Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.

Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA.

AIDS. 2000 May 26;14(8):959-69.

PMID:
10853977
8.

Net benefits of resistance testing directed therapy compared with standard of care in HIV-infected patients with virological failure: A meta-analysis.

Ena J, Ruiz de Apodaca RF, Amador C, Benito C, Pasquau F.

Enferm Infecc Microbiol Clin. 2006 Apr;24(4):232-7.

PMID:
16725082
9.

HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.

Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM.

AIDS. 2008 Aug 20;22(13):1583-8. doi: 10.1097/QAD.0b013e328305bd77.

PMID:
18670217
10.
11.

Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.

Hunt PW, Deeks SG, Rodriguez B, Valdez H, Shade SB, Abrams DI, Kitahata MM, Krone M, Neilands TB, Brand RJ, Lederman MM, Martin JN.

AIDS. 2003 Sep 5;17(13):1907-15.

PMID:
12960823
12.

Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.

Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, Fiscus SA, Spector SA, Squires KE, Fischl MA, Hammer SM.

Ann Intern Med. 2001 Dec 4;135(11):954-64.

PMID:
11730396
13.

Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients.

Ibáñez A, Puig T, Elias J, Clotet B, Ruiz L, Martínez MA.

AIDS. 1999 Jun 18;13(9):1045-9.

PMID:
10397534
14.
15.

A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.

Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, Nadler J, Verbiest W, Hertogs K, Ames M, Rinehart AR, Graham NM; VIRA3001 Study Team.

AIDS. 2002 Mar 8;16(4):579-88.

PMID:
11873001
16.

Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA.

Cu-Uvin S, Caliendo AM, Reinert S, Chang A, Juliano-Remollino C, Flanigan TP, Mayer KH, Carpenter CC.

AIDS. 2000 Mar 10;14(4):415-21.

PMID:
10770544
17.

Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.

Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, van Lunzen J, Katzenstein TL, Antunes F, Lundgren JD, Clotet B.

Arch Intern Med. 2000 Apr 24;160(8):1123-32.

PMID:
10789605
18.
19.

Effective treatment of patients in a deep salvage situation with "non-active HAART": experiences with the expert advice system RADATA.

Lorenzen T, Walther I, Stoehr A, Salzberger B, Plettenberg A; Radata Study Group.

Infection. 2009 Dec;37(6):528-33. doi: 10.1007/s15010-009-9022-6. Epub 2009 Oct 13.

PMID:
19826762
20.

Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.

Nadler JP, Gathe JC, Pollard RB, Richmond GJ, Liao Q, Griffith S, Lancaster CT, Hernandez JE, Pappa KA; ESS40011 (STARR) Study Team.

BMC Infect Dis. 2003 Jun 10;3:10.

Supplemental Content

Support Center